Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow ZTS
Zoetis Inc. (ZTS) Shares outstanding
Zoetis Inc.'s shares outstanding at the end of fiscal 2025 was $443.8M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $417.7M. Over the past ten years it has ranged from $443.8M (fiscal 2025) to $502.0M (fiscal 2015) — the current reading is the lowest in ten years. Zoetis Inc. ranks 8th of 83 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $443.8M | (2.42%) |
| FY2024 | $454.8M | (1.61%) |
| FY2023 | $462.3M | (1.73%) |
| FY2022 | $470.4M | (1.33%) |
| FY2021 | $476.7M | (0.39%) |
| FY2020 | $478.6M | (0.67%) |
| FY2019 | $481.8M | (1.05%) |
| FY2018 | $486.9M | (1.27%) |
| FY2017 | $493.2M | (1.02%) |
| FY2016 | $498.2M | (0.76%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $417.7M | (1.11%) |
| Mar 2026 | $422.4M | (4.83%) |
| Dec 2025 | $443.8M | 0.14% |
| Sep 2025 | $443.2M | (0.52%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $4.6B |
| TAK Takeda Pharmaceutical Co. compare | $3.2B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.2B |
| VTRS Viatris Inc. compare | $1.2B |
| RDY Dr. Reddy's Laboratories Ltd compare | $783.3M |
| ELAN Elanco Animal Health Incorporated compare | $505.9M |
| ZTS Zoetis Inc. | $417.7M |
| NBIX Neurocrine Biosciences, Inc. compare | $104.2M |
| UTHR United Therapeutics Corporation compare | $45.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement